Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 470

1.

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, et al.

Bone. 1995 Oct;17(4):383-90.

PMID:
8573412
[PubMed - indexed for MEDLINE]
2.

Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.

Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Ortolani S, et al.

Osteoporos Int. 1993;3 Suppl 3:S21-7.

PMID:
8298199
[PubMed - indexed for MEDLINE]
3.

The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.

Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.

Rheumatol Int. 2005 Nov;26(1):21-9. Epub 2005 Feb 2.

PMID:
15688191
[PubMed - indexed for MEDLINE]
4.

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.

Bone. 1996 Feb;18(2):141-50. Erratum in: Bone 1996 Jul;19(1):78.

PMID:
8833208
[PubMed - indexed for MEDLINE]
5.

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.

Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S.

J Bone Miner Res. 1994 Nov;9(11):1833-7.

PMID:
7863833
[PubMed - indexed for MEDLINE]
7.

The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.

Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.

J Bone Miner Metab. 2009;27(4):471-8. doi: 10.1007/s00774-009-0057-7. Epub 2009 Apr 3.

PMID:
19343272
[PubMed - indexed for MEDLINE]
8.

Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.

Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.

Clin Rheumatol. 2005 Jun;24(3):232-8. Epub 2005 Jan 13.

PMID:
15647969
[PubMed - indexed for MEDLINE]
9.

The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.

Colpan L, Gur A, Cevik R, Nas K, Sarac AJ.

Maturitas. 2005 Jul 16;51(3):246-53.

PMID:
15978968
[PubMed - indexed for MEDLINE]
10.

Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.

Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.

Calcif Tissue Int. 1996 Jul;59(1):6-11.

PMID:
8661976
[PubMed - indexed for MEDLINE]
11.

Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.

Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C.

Am J Med. 1990 Jul;89(1):1-6.

PMID:
2152594
[PubMed - indexed for MEDLINE]
13.

Early effect of nasal salmon calcitonin on the bone marker Crosslaps.

Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.

Rheumatol Int. 2006 Feb;26(4):288-91. Epub 2005 May 5.

PMID:
15875189
[PubMed - indexed for MEDLINE]
14.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
[PubMed - indexed for MEDLINE]
15.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
[PubMed - indexed for MEDLINE]
16.
17.

A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.

Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS; Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.

J Bone Miner Res. 2012 Aug;27(8):1821-9. doi: 10.1002/jbmr.1602.

PMID:
22437792
[PubMed - indexed for MEDLINE]
18.

[Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].

Stĕpán J, Formánková J, Masatová A, Michalský M, Rosenová Z.

Cas Lek Cesk. 1997 Apr 16;136(8):242-8. Czech.

PMID:
9264868
[PubMed - indexed for MEDLINE]
19.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
[PubMed - indexed for MEDLINE]
20.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

PMID:
7477143
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk